PCSK9 and cardiovascular disorder: Randomized clinical trials (RCTs) have shown that lowering LDL-C reduces cardiovascular disease (CVD) events and mortality,7 and intensive LDL-C lowering further reduces CVD events compared with standard LDL-C lowering.8,9,10 However, no reduction in all-cause mortality or CVD mortality has been shown in trials comparing more intensive and less intensive statin therapy,11,12,13 or in trials adding PCSK9 (proprotein convertase subtilisin and kexin type 9) inhibitors9 or ezetimibe10 to background statin therapy.